NewAmsterdam Pharma N.V. (NAMSW)
11.30
-1.32 (-10.46%)
At close: Jan 28, 2025, 2:18 PM
undefined% (undefined)
| Bid | 9.97 |
| Market Cap | 2.42B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | 10.62 |
| Volume | 301 |
| Avg. Volume (20D) | 6,830 |
| Open | 11.60 |
| Previous Close | 12.62 |
| Day's Range | 11.30 - 11.60 |
| 52-Week Range | 5.52 - 16.75 |
| Beta | undefined |
About NAMSW
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, focuses on improving patient care in populations with metabolic diseases. Its lead investigational candidate, obicetrapib, is a novel, selective inhibitor that targets the Cholesteryl Ester Transfer Protein (CETP), which has been clinically shown to reduce low-density lipoprotein cholesterol (LDL-C) while at the same time substantially increase high-density lipoprotein ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 10, 2021
Employees 62
Stock Exchange NASDAQ
Ticker Symbol NAMSW